G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, a (CDK) 4/6 inhibitor that is in Phase III clinical trials for patients with first line colorectal cancer; Phase III clinical trial for the treatment of first line triple negative breast cancer; Phase II clinical trial for patients with first line bladder cancer; Phase II clinical trial for patients with combination with the antibody-drug conjugate; and Phase II clinical trial for the treatment of neoadjuvant breast cancer. In addition, the company develops lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase IIa clinical trials for the treatment of estrogen receptor-positive and HER2-negative breast cancer. The company has a license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.

G1 Therapeutics, Inc.

G1 Therapeutics, Inc. is a commercial-stage oncology company focused on the development and commercialization of next generation anti-cancer therapies. Led by a team with a deep understanding of the biology of cancer and extensive development and commercialization expertise, G1 is advancing its mission to improve the lives of those affected by cancer, including by commercializing the Company’s first commercial product, COSELA® (trilaciclib). G1 is also executing a development program, with a deep clinical pipeline evaluating targeted cancer therapies in a variety of solid tumors, including breast, lung, and bladder cancers.

G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics. View our social community guidelines here: https://www.g1therapeutics.com/social-guidelines

Hercules Capital

Cowen Investment Management

Hatteras Venture Partners

Aju IB Investment

Tavistock Life Sciences

Lumira Ventures

Mountain Group Capital

Cormorant Asset Management

Cowen Group

Eshelman Ventures

Franklin Templeton

#DYK Since the first approval of an Antibody-Drug Conjugate #ADC in 2000, there have been 12 FDA approved ADCs and over 170 novel ADCs in #clinicaldevelopment? 

#DYK: #BreastCancer is the most common type of cancer? 1 in 8 women in the United States will be diagnosed with breast cancer in her lifetime. Learn more from the National Breast Cancer Foundation, Inc. Cancer Foundation: https://bit.ly/3ZL2whj 

#ICYMI: Our team member Dianna, Oncology Medical Science Liaison, shared how her #BreastCancer diagnosis changed her perspectives on life and in her career. Learn more: bit.ly/3rtWfKb

Early detection and intervention can save lives. If you notice persistent cough, chest pain, or unexplained weight loss, these can be early indicators of #LungCancer. This #CancerScreenWeek learn more about the importance of regular screenings. https://bit.ly/3ZRiOVP

We're excited to present a post hoc analysis at #SABCS23 describing the long term impact of our investigational drug on subsequent anticancer therapy for #TripleNegative #BreastCancer. Read more here: https://bit.ly/3GvwPQ6. #TNBC

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

customer_profile

peers

news_basic

valuation

NASDAQ:GTHX

G1 Therapeutics, Inc.

Last Close

7.15

17/09 19:56

Market Cap

145.87M

Beta: 1.92

Volume Today

1.10M

Avg: 1.22M

PE Ratio

−3.00

PFCF: −4.05